Cumberland Pharmaceuticals Inc. has announced the latest results from its Phase 2 FIGHT DMD trial evaluating ifetroban, an oral therapy for Duchenne muscular dystrophy (DMD) heart disease. These findings, which were presented at the Parent Project Muscular Dystrophy Annual Conference, demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients. The trial results, featuring new pharmacokinetic and cardiac biomarker data, indicate potential improvements in heart function and reduction in cardiac damage markers. The complete presentation is available on Cumberland's website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。